Related Experiment Videos
Redefining antidepressant efficacy toward long-term recovery
1Department of Psychiatry, Western Psychiatric Institute, University of Pittsburgh, PA 15213, USA.
The Journal of Clinical Psychiatry
|May 11, 1999
Summary
Long-term antidepressant therapy, including selective serotonin reuptake inhibitors (SSRIs) and venlafaxine, significantly reduces major depression relapse rates. Full remission and sustained recovery are key goals for effective treatment.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Research
Background:
- Major depression relapse is common, affecting 30-50% of patients within 6 months.
- Full remission and long-term recovery are crucial treatment goals, surpassing short-term response.
- High-risk patients include those not fully remitting during acute therapy.
Purpose of the Study:
- To investigate the long-term efficacy and recovery rates of antidepressant pharmacotherapy.
- To evaluate preventative pharmacotherapy for reducing recurrent depression.
- To highlight the need for prospective, long-term studies in antidepressant treatment.
Main Methods:
- Review of prospective, long-term studies on antidepressant therapy.
- Analysis of data on imipramine, SSRIs, nefazodone, mirtazapine, and venlafaxine.
- Inclusion of extension and discontinuation study designs.
Main Results:
- Continuous imipramine treatment for 3-5 years significantly reduced recurrence rates.
- Newer agents like SSRIs, nefazodone, and mirtazapine showed lower relapse rates versus placebo.
- Venlafaxine demonstrated long-term efficacy in extension and discontinuation studies.
Conclusions:
- Antidepressants, including SNRIs like venlafaxine, are effective for long-term management.
- Long-term therapy is essential for achieving full remission and preventing relapse in major depression.
- Evidence supports the tolerability and efficacy of extended antidepressant use.